Loading...
XSHE002907
Market cap690mUSD
Jan 10, Last price  
12.13CNY
1D
-4.41%
1Q
-7.19%
IPO
69.18%
Name

Chongqing Pharscin Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002907 chart
P/E
154.91
P/S
7.32
EPS
0.08
Div Yield, %
0.60%
Shrs. gr., 5y
0.86%
Rev. gr., 5y
-0.34%
Revenues
692m
-11.93%
347,365,952425,904,327469,319,111551,667,001592,095,363703,415,290842,064,017882,474,476846,141,123785,182,813691,542,793
Net income
33m
-66.77%
28,946,96658,754,67473,836,22095,707,727111,987,474137,371,811169,746,081119,187,20091,780,35898,400,63532,699,150
CFO
219m
+1,581.42%
020,221,31766,101,05757,732,72881,339,87831,795,46565,915,552113,637,98882,850,65913,044,979219,341,327
Dividend
Sep 10, 20240.035 CNY/sh
Earnings
May 22, 2025

Profile

Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, hard capsules, soft capsules, powder injections, freeze-dried powder injections, small volume injections, and API synthesis. It provides its products in the areas of CNS, digestion, otolaryngology, oncology, cardiovascular, and cerebrovascular related diseases. Chongqing Pharscin Pharmaceutical Co., Ltd. was founded in 1996 and is headquartered in Chongqing, China.
URL
http://www.pharscin.com/
IPO date
Oct 20, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
691,543
-11.93%
785,183
-7.20%
Cost of revenue
602,846
632,189
Unusual Expense (Income)
NOPBT
88,697
152,994
NOPBT Margin
12.83%
19.49%
Operating Taxes
10,098
9,840
Tax Rate
11.38%
6.43%
NOPAT
78,599
143,153
Net income
32,699
-66.77%
98,401
7.21%
Dividends
(30,166)
(20,004)
Dividend yield
0.47%
0.24%
Proceeds from repurchase of equity
2,041
BB yield
-0.02%
Debt
Debt current
112
Long-term debt
280
115
Deferred revenue
43,034
43,595
Other long-term liabilities
2
Net debt
(535,671)
(606,746)
Cash flow
Cash from operating activities
219,341
13,045
CAPEX
(92,818)
Cash from investing activities
(157,830)
Cash from financing activities
(30,229)
FCF
74,028
109,891
Balance
Cash
437,565
503,529
Long term investments
98,386
103,445
Excess cash
501,374
567,715
Stockholders' equity
1,066,288
1,160,292
Invested Capital
1,159,722
1,067,558
ROIC
7.06%
13.25%
ROCE
5.33%
9.35%
EV
Common stock shares outstanding
417,614
403,116
Price
15.45
-24.12%
20.36
12.80%
Market cap
6,452,131
-21.39%
8,207,443
13.35%
EV
5,916,460
7,600,697
EBITDA
170,803
227,687
EV/EBITDA
34.64
33.38
Interest
1,013
14,415
Interest/NOPBT
1.14%
9.42%